Drug Trial Radar · NCT01960348
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Nov 2013
Primary completion
Aug 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Oct 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
Conditions
- TTR-mediated Amyloidosis
- Amyloidosis, Hereditary
- Amyloid Neuropathies, Familial
- Familial Amyloid Polyneuropathies
- Amyloid Neuropathies
- Amyloidosis, Hereditary, Transthyretin-Related
Interventions
patisiran (ALN-TTR02)Drug
administered by intravenous (IV) infusion
Sterile Normal Saline (0.9% NaCl)Drug
administered by intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Neuropathy Impairment Score +7 (mNIS+7)Time frame: 18mo
Locations
52 sites in 21 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Mesa, California
Clinical Trial Site
Orange, California
Clinical Trial Site
Denver, Colorado
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Detroit, Michigan
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Durham, North Carolina
Clinical Trial Site
Portland, Oregon
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Westmead, Australia
Clinical Trial Site
Ribeirão Preto, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Vancouver, British Columbia, Canada
Clinical Trial Site
Nicosia, Cyprus
Clinical Trial Site
Bourdeaux, France
Clinical Trial Site
Créteil, France
Clinical Trial Site
Le Kremlin-Bicêtre, France
Clinical Trial Site
Lille, France
Clinical Trial Site
Marseille, France
Clinical Trial Site
Heidelberg, Germany
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Regensburg, Germany
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Sicily, Italy
Clinical Trial Site
Aichi, Japan
Clinical Trial Site
Kumamoto, Japan
Clinical Trial Site
Matsumoto, Nagano, Japan
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
Mexico City, Mexico
Clinical Trial Site
Groningen, Netherlands
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Porto, Portugal
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.